Contra-indicated in patients with severe renal impairment (including end stage renal disease, kidney transplant recipients or patients on dialysis), tumor lysis syndrome or Lesch-Nylan syndrome.
Duzallo is lesinurad and allopurinol (see separate entry).
- TRADE NAMES: Duzallo (AstraZeneca); Zurampic (AstraZeneca)
- INDICATIONS: Gout-associated hyperuricemia (in combination with a xanthine oxidase inhibitor)
- CLASS: URAT1 inhibitor, Uricosuric
- HALF-LIFE: 5 hours
- FDA APPROVAL DATE: 12/22/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Carbamazepine, CYP2C9 inducers or inhibitors, CYP3A substrates, Fluconazole, Rifampin, Valproic Acid - PREGNANCY: No available data
- See adverse reactions attributed to class:
RISK OF ACUTE RENAL FAILURE, MORE COMMON WHEN USED WITHOUT A XANTHINE OXIDASE INHIBITOR
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
